Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments a live attenuated virus composition includes but is not limited to one or more live attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live attenuated alphavirus. In other embodiments the live attenuated virus composition may be a vaccine composition. In yet other compositions a live attenuated alphavirus composition may include HEPES buffer. In other embodiments the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.
